Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Cognitive reserve and symptom experience in multiple sclerosis: A buffer to disability progression over time?
Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine.
Mechanics in Neuronal Development and Repair.
Disruption of melatonin circadian rhythm production is related to multiple sclerosis severity: A preliminary study.
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis.
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis.
Oligodendroglial markers in the cuprizone model of CNS de- and remyelination.
Brain MRI abnormalities in Brazilian patients with neuromyelitis optica.
Development and characterization of a clinically compliant xeno-free culture medium in good manufacturing practice for human multipotent mesenchymal stem cells.
HLA-DRB1 does not have a role in clinical response to interferon-beta among Iranian multiple sclerosis patients.
Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study.
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.
Brain Innate Immunity In The Regulation Of Neuroinflammation: Therapeutic Strategies By Modulating Cd200-Cd200r Interaction Involve The Cannabinoid System.
Podoplanin is an inflammatory protein upregulated in Th17 cells in SKG arthritic joints.
Role of IL-16 in CD4(+) T cell-mediated regulation of relapsing multiple sclerosis.
Improved assessment of multiple sclerosis lesion segmentation agreement via detection and outline error estimates.
UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production.
A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor.
CD14 is a key organizer of microglial responses to CNS infection and injury.
Multifocal visual evoked potentials are influenced by variable contrast stimulation in MS.
Cognitive functioning and subjective quality of life in relapsing-remitting multiple sclerosis patients before and after percutaneous transluminal angioplasty: a preliminary report.
Shared HLA Class II in Six Autoimmune Diseases in Latin America: A Meta-Analysis.
A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis.
Occupational Exposure and Risk of Central Nervous System Demyelination.
Pages
« first
‹ previous
…
209
210
211
212
213
214
215
216
217
…
next ›
last »